This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation. Providing…
Detailed assessment and forecast for leading products by value to 2012 and beyond
An assessment of patent expiry and challenges
A review of products in late phase research which could impact generic developments
Patent expiry opportunities to 2015
All major sectors
(Alzheimer’s and Parkinson’s Diseases)
Sales of the leading branded drugs used to treat the major CNS conditions could exceed US$70 billion in 2008, with a number of these losing patent protection in the coming years.
This important new strategic report evaluates the CNS generic drug market sector and answers key questions such as:
What is the patent and data exclusivity status of Shire’s ADHD drug Adderall?
What impact on sales of GSK’s Seroxat/Paxil will generic competition have from 2007?
What opportunities exist for Wyeth’s valuable SSNRI Effexor?
What strategies are sanofi-aventis employing in defence of its best selling insomnia treatment Ambien?
Only Exelon is currently available generically for the treatment of Alzheimer’s – what is the potential of the other leading treatments Aricept (Eisai), Razadyne (Janssen) and Namenda (Forest Labs)?
What’s in the pipeline? New branded products that will compete with generics in the future.
Why will sales of Eli Lilly’s Zyprexa remain constant over the next 5 years despite rising generic availability?
What are Dr Reddy’s CNS drug interests?
In 2007, Caraco Pharmaceuticals received 3 ANDA approvals for CNS drugs. What were they and in what dosages?